Consistent with those findings, the results of our study indicated that AML cells with high TP53INP2 expression were more sensitive to TRAIL in vitro and in CDX mouse models and that the suppression of TP53INP2 expression significantly reduced vulnerability to TRAIL. The gene discussed is TP53INP2; the disease is acute myeloid leukemia.